Skip to main content
Clinical Trials/NCT01635751
NCT01635751CompletedPhase 1

A Randomized, Open-label, 3-way Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects

GL Pharm Tech Corporation1 site in 1 country30 target enrollmentStarted: October 2012Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Sponsor
Enrollment
30
Locations
1
Primary Endpoint
Cmax

Study Overview

Brief Summary

The purpose of this clinical trial is to compare the pharmacokinetic characteristics of GLA5PR GLARS tablet 150mg and Lyrica Capsule 75mg.

GLA5PR GLARS tablet 150mg is a new once-a-day formulation which is made by GL Pharm Tech corporation.

GLARS(Geometrically Long Absorption Regulated System) is new solution to sustained absorption by extending the absorption Site.

To overcome the shortcomings of the currently existing sustained release drug delivery technologies the investigators have recently developed a novel drug delivery system to enable a drug to be dissolved irrespective of the surrounding environment and further absorbed up to colon. The investigators coined this "Geometrically Long Absorption Regulated System(GLARS)".

Detailed Description

Basically, this system is a triple-layered tablet, comprised of upper and lower layers that swell and draw a sufficient amount of water, plus a highly water - soluble middle layer that rapidly draw water into the tablet core simultaneously.

The water drawn into the tablet (about 3 to 4 times the weight of the tablet itself) functions as an additional media which enables additional and later drug release out of the dosage form. This serves to overcome the shortage of surrounding media that has been reported to be one of the key reasons for malabsorption of a drug in colon.

As the middle layer induces a rapid water draw into the tablet core, the penetrated water also diffuses to the upper and lower layers, which makes the tablet to rapidly swell and controls drug release.

At virtually the same time, the swollen upper and lower layers form to surround a lateral side of the middle layer, which can, in turn, further control drug release.

This relatively rigid swollen matrix structure makes drug release not affected by surrounding mechanical flux, which can provide relatively consistent in vivo drug release irrespective of degree of gastrointestinal motility.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
20 Years to 45 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • 20~45 years old, Healthy Adult Male Subject
  • ≥ 50kg(Body Weight) and Ideal Body Weight ≤ ±20%

Exclusion Criteria

  • ALT or AST > 1.25(Upper Normal Range)
  • Total Bilirubin > 1.5 (Upper Normal Range)

Arms & Interventions

GLA5PR GLARS tablet 150mg(fasted)

Experimental

Intervention: Pregabalin (Drug)

GLA5PR GLARS tablet 150mg(after high fat meal)

Experimental

Intervention: Pregabalin (Drug)

Lyrica Capsule 75mg(fasted)

Active Comparator

Intervention: Pregabalin (Drug)

Outcomes

Primary Outcomes

Cmax

Time Frame: 36hrs

Pharmacokinetic of Pregabalin

Tmax

Time Frame: 36hrs

Pharmacokinetic of Pregabalin

AUC0-36h

Time Frame: 36hrs

Pharmacokinetic of Pregabalin

AUC0-∞

Time Frame: 36hrs

Pharmacokinetic of Pregabalin

CL/F

Time Frame: 36hrs

Pharmacokinetic of Pregabalin

Vd/F

Time Frame: 36hrs

Pharmacokinetic of Pregabalin

T1/2

Time Frame: 36hrs

Pharmacokinetic of Pregabalin

Secondary Outcomes

  • Safety Monitoring(23 days)

Investigators

Sponsor
GL Pharm Tech Corporation
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

A Clinical Trial to Compare The... | Clinical Trial